Drug intelligence / Profile preview

MMV609

Development stage: Preclinical
Lead developer: Medicines for Malaria Venture
Modality: Small Molecules

Overview

MMV609 is a small molecule antimalarial compound currently in early preclinical development. It is being developed by the Medicines for Malaria Venture (MMV) in collaboration with the University of Kentucky. The compound targets the asexual blood stages of the malaria parasite and exhibits transmission-reduction properties. It is intended for the treatment of uncomplicated malaria and as a tool for resistance management, aligning with the Target Product Profile 1 (TPP-1) for new antimalarials. As of the current reporting, the specific molecular target and active ingredient have not been publicly disclosed.

Targets

PfATP4 (Plasmodium falciparum ATPase 4)

Beyond the preview

Go deeper on MMV609.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MMV609.

Explore the full profile